Last reviewed · How we verify
Oral sildenafil
Oral sildenafil, marketed by N4 Pharma UK Ltd., holds a position in the erectile dysfunction market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and broad market acceptance. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Oral sildenafil |
|---|---|
| Also known as | Viagra, Integra, SST-6006 |
| Sponsor | N4 Pharma UK Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Radial Shockwave Therapy for Erectile Dysfunction (NA)
- Asciminib With or Without Sildenafil for Brain Tumors (EARLY_PHASE1)
- Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT) (PHASE2, PHASE3)
- Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD (PHASE2)
- Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support (EARLY_PHASE1)
- Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study) (PHASE1)
- IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (PHASE1)
- PK and Onset of Hezkue Oral Sildenafil Suspension After Alcohol Consumption (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral sildenafil CI brief — competitive landscape report
- Oral sildenafil updates RSS · CI watch RSS
- N4 Pharma UK Ltd. portfolio CI